Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccinations

Vaccinations

Cross-reactivity

Cross-reactivity

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Comparison of laboratory-developed methods for aztreonam plus ceftazidime-avibactam antimicrobial susceptibility testing for metallo-beta-lactamase-producing Enterobacterales.

Journal of clinical microbiology·2026

Same author

Enhancing, controlling, and sterilizing dengue immunity and the development of broadly protective responses.

medRxiv : the preprint server for health sciences·2026

Same author

Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine.

Nature medicine·2026

Same author

Plazomicin activity against carbapenem-resistant Escherichia coli: A brief report.

Indian journal of medical microbiology·2026

Same author

Corrigendum to 'Localized Inflammation in Dengue Vaccine-Induced Skin Rash Is Not Associated with Continuous Presence of Dengue Virus Genome' Journal of Investigative Dermatology Volume 145, Issue 8, August 2025, Pages 2021-2033.e3.

The Journal of investigative dermatology·2026

Search research articles

Related Experiment Video

Updated: Feb 26, 2026

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction

Published on: November 1, 2018

Dengue vaccines: implications for dengue control.

Matthew L Robinson¹, Anna P Durbin

¹aDivision of Infectious Disease, Johns Hopkins School of Medicine bDepartment of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Current Opinion in Infectious Diseases

|July 19, 2017

Summary

The new dengue vaccine shows 60% efficacy but is most effective in those previously exposed to the virus. Its widespread use for global dengue control is limited, necessitating further research on alternative vaccines and integrated strategies.

More Related Videos

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection

Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection

Published on: January 26, 2024

Related Experiment Videos

Last Updated: Feb 26, 2026

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction

Published on: November 1, 2018

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection

Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection

Published on: January 26, 2024

Area of Science:

Arbovirology
Vaccinology
Epidemiology

Background:

Dengue is a significant global health concern caused by arboviruses.
Decades of research have led to the development of the first approved tetravalent dengue vaccine.
Modeling vaccine impact is crucial for global dengue control strategies.

Purpose of the Study:

To evaluate the potential impact of the approved dengue vaccine on global control.
To discuss data-driven insights into dengue vaccine deployment.
To analyze vaccine efficacy data in the context of global dengue burden.

Main Methods:

Utilized recently available vaccine efficacy data.
Employed mathematical modeling to predict population-level impact.
Reviewed Phase 3 efficacy trial results for the approved dengue vaccine.

Main Results:

The approved tetravalent dengue vaccine (chimeric yellow fever-dengue) demonstrated 60% efficacy against dengue illness.
Vaccine efficacy is limited and potentially increases severity in dengue-naïve individuals.
WHO recommends vaccination for populations with at least 70% dengue seropositivity.

Conclusions:

The current dengue vaccine's favorable profile is restricted to dengue-experienced individuals, limiting global control potential.
Further evaluation of long-term durability and alternative vaccine candidates is essential.
Synergistic strategies combining vaccination with vector control may enhance dengue management.